Global Custom-Compounded Therapy Market

Custom-Compounded Therapy Comprehensive Study by Application (Paediatric, Adult, Geriatric, Veterinary), Distribution Channel (Hospital pharmacy, Compounding pharmacy, Others), Therapeutic Area (Hormone replacement, Pain management, Dermatology, Specialty drugs, Nutritional supplements, Others) Players and Region - Global Market Outlook to 2030

Custom-Compounded Therapy Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Custom-Compounded Therapy
Bioidentical hormone therapy is another name for custom compounded therapy. Man-made hormones that are equivalent to hormones produced by the human body are known as bioidentical hormones. Bioidentical hormones are used to treat men and women who have low or unbalanced hormone levels.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Custom-Compounded Therapy market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Fagron (Netherlands), Specialist Pharmacy (United Kingdom), Nova Laboratories (United Kingdom), Athenex Pharma Solutions (New York), ImprimisRx (California), Fresenius Kabi (Germany), Baxter (United States), B. Braun (Germany) and Galenic Laboratories (France) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Pencol Compounding Pharmacy (United States), McKesson Corporation (United States) and Clinigen Group (United Kingdom).

Segmentation Overview
AMA Research has segmented the market of Global Custom-Compounded Therapy market by , Application (Paediatric, Adult, Geriatric and Veterinary) and Region.



On the basis of geography, the market of Custom-Compounded Therapy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Distribution Channel, the sub-segment i.e. Hospital pharmacy will boost the Custom-Compounded Therapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Therapeutic Area, the sub-segment i.e. Hormone replacement will boost the Custom-Compounded Therapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
New therapy are developing

Market Growth Drivers:
Increasing demand for personalized medicine

Challenges:
Increasing demand for customized compound therapies in few years due to awareness of health

Restraints:
Increasing in side effects of humans

Opportunities:
Increasing knowledge in consumers

Market Leaders and their expansionary development strategies
In October 2023, FarmaKeio Custom Compounding, a trailblazing pharmaceutical company, has acquired of its newest location in Conway. This new facility represents a significant advancement in FarmaKeio's mission to support the revolution of healthcare by providing personalized compounded medications and service excellence to patients and practitioners across the country.
In 2021, MEDISCA declared that in June it would equal up to USD 100,000 in donations to the Alliance for Pharmacy Compounding, Media Fund Campaign, encouraging investments to support APC’s nationwide marketing and lobbying effort to secure compounded hormone therapy.


Key Target Audience
Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Paediatric
  • Adult
  • Geriatric
  • Veterinary
By Distribution Channel
  • Hospital pharmacy
  • Compounding pharmacy
  • Others

By Therapeutic Area
  • Hormone replacement
  • Pain management
  • Dermatology
  • Specialty drugs
  • Nutritional supplements
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing demand for personalized medicine
    • 3.3. Market Challenges
      • 3.3.1. Increasing demand for customized compound therapies in few years due to awareness of health
    • 3.4. Market Trends
      • 3.4.1. New therapy are developing
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Custom-Compounded Therapy, by Application, Distribution Channel, Therapeutic Area and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Custom-Compounded Therapy (Value)
      • 5.2.1. Global Custom-Compounded Therapy by: Application (Value)
        • 5.2.1.1. Paediatric
        • 5.2.1.2. Adult
        • 5.2.1.3. Geriatric
        • 5.2.1.4. Veterinary
      • 5.2.2. Global Custom-Compounded Therapy by: Distribution Channel (Value)
        • 5.2.2.1. Hospital pharmacy
        • 5.2.2.2. Compounding pharmacy
        • 5.2.2.3. Others
      • 5.2.3. Global Custom-Compounded Therapy by: Therapeutic Area (Value)
        • 5.2.3.1. Hormone replacement
        • 5.2.3.2. Pain management
        • 5.2.3.3. Dermatology
        • 5.2.3.4. Specialty drugs
        • 5.2.3.5. Nutritional supplements
        • 5.2.3.6. Others
      • 5.2.4. Global Custom-Compounded Therapy Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Custom-Compounded Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Fagron (Netherlands)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Specialist Pharmacy (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Nova Laboratories (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Athenex Pharma Solutions (New York)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. ImprimisRx (California)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Fresenius Kabi (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Baxter (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. B. Braun (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Galenic Laboratories (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Custom-Compounded Therapy Sale, by Application, Distribution Channel, Therapeutic Area and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Custom-Compounded Therapy (Value)
      • 7.2.1. Global Custom-Compounded Therapy by: Application (Value)
        • 7.2.1.1. Paediatric
        • 7.2.1.2. Adult
        • 7.2.1.3. Geriatric
        • 7.2.1.4. Veterinary
      • 7.2.2. Global Custom-Compounded Therapy by: Distribution Channel (Value)
        • 7.2.2.1. Hospital pharmacy
        • 7.2.2.2. Compounding pharmacy
        • 7.2.2.3. Others
      • 7.2.3. Global Custom-Compounded Therapy by: Therapeutic Area (Value)
        • 7.2.3.1. Hormone replacement
        • 7.2.3.2. Pain management
        • 7.2.3.3. Dermatology
        • 7.2.3.4. Specialty drugs
        • 7.2.3.5. Nutritional supplements
        • 7.2.3.6. Others
      • 7.2.4. Global Custom-Compounded Therapy Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Custom-Compounded Therapy: by Application(USD Million)
  • Table 2. Custom-Compounded Therapy Paediatric , by Region USD Million (2018-2023)
  • Table 3. Custom-Compounded Therapy Adult , by Region USD Million (2018-2023)
  • Table 4. Custom-Compounded Therapy Geriatric , by Region USD Million (2018-2023)
  • Table 5. Custom-Compounded Therapy Veterinary , by Region USD Million (2018-2023)
  • Table 6. Custom-Compounded Therapy: by Distribution Channel(USD Million)
  • Table 7. Custom-Compounded Therapy Hospital pharmacy , by Region USD Million (2018-2023)
  • Table 8. Custom-Compounded Therapy Compounding pharmacy , by Region USD Million (2018-2023)
  • Table 9. Custom-Compounded Therapy Others , by Region USD Million (2018-2023)
  • Table 10. Custom-Compounded Therapy: by Therapeutic Area(USD Million)
  • Table 11. Custom-Compounded Therapy Hormone replacement , by Region USD Million (2018-2023)
  • Table 12. Custom-Compounded Therapy Pain management , by Region USD Million (2018-2023)
  • Table 13. Custom-Compounded Therapy Dermatology , by Region USD Million (2018-2023)
  • Table 14. Custom-Compounded Therapy Specialty drugs , by Region USD Million (2018-2023)
  • Table 15. Custom-Compounded Therapy Nutritional supplements , by Region USD Million (2018-2023)
  • Table 16. Custom-Compounded Therapy Others , by Region USD Million (2018-2023)
  • Table 17. South America Custom-Compounded Therapy, by Country USD Million (2018-2023)
  • Table 18. South America Custom-Compounded Therapy, by Application USD Million (2018-2023)
  • Table 19. South America Custom-Compounded Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 20. South America Custom-Compounded Therapy, by Therapeutic Area USD Million (2018-2023)
  • Table 21. Brazil Custom-Compounded Therapy, by Application USD Million (2018-2023)
  • Table 22. Brazil Custom-Compounded Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 23. Brazil Custom-Compounded Therapy, by Therapeutic Area USD Million (2018-2023)
  • Table 24. Argentina Custom-Compounded Therapy, by Application USD Million (2018-2023)
  • Table 25. Argentina Custom-Compounded Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 26. Argentina Custom-Compounded Therapy, by Therapeutic Area USD Million (2018-2023)
  • Table 27. Rest of South America Custom-Compounded Therapy, by Application USD Million (2018-2023)
  • Table 28. Rest of South America Custom-Compounded Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 29. Rest of South America Custom-Compounded Therapy, by Therapeutic Area USD Million (2018-2023)
  • Table 30. Asia Pacific Custom-Compounded Therapy, by Country USD Million (2018-2023)
  • Table 31. Asia Pacific Custom-Compounded Therapy, by Application USD Million (2018-2023)
  • Table 32. Asia Pacific Custom-Compounded Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 33. Asia Pacific Custom-Compounded Therapy, by Therapeutic Area USD Million (2018-2023)
  • Table 34. China Custom-Compounded Therapy, by Application USD Million (2018-2023)
  • Table 35. China Custom-Compounded Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 36. China Custom-Compounded Therapy, by Therapeutic Area USD Million (2018-2023)
  • Table 37. Japan Custom-Compounded Therapy, by Application USD Million (2018-2023)
  • Table 38. Japan Custom-Compounded Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 39. Japan Custom-Compounded Therapy, by Therapeutic Area USD Million (2018-2023)
  • Table 40. India Custom-Compounded Therapy, by Application USD Million (2018-2023)
  • Table 41. India Custom-Compounded Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 42. India Custom-Compounded Therapy, by Therapeutic Area USD Million (2018-2023)
  • Table 43. South Korea Custom-Compounded Therapy, by Application USD Million (2018-2023)
  • Table 44. South Korea Custom-Compounded Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 45. South Korea Custom-Compounded Therapy, by Therapeutic Area USD Million (2018-2023)
  • Table 46. Taiwan Custom-Compounded Therapy, by Application USD Million (2018-2023)
  • Table 47. Taiwan Custom-Compounded Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 48. Taiwan Custom-Compounded Therapy, by Therapeutic Area USD Million (2018-2023)
  • Table 49. Australia Custom-Compounded Therapy, by Application USD Million (2018-2023)
  • Table 50. Australia Custom-Compounded Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 51. Australia Custom-Compounded Therapy, by Therapeutic Area USD Million (2018-2023)
  • Table 52. Rest of Asia-Pacific Custom-Compounded Therapy, by Application USD Million (2018-2023)
  • Table 53. Rest of Asia-Pacific Custom-Compounded Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 54. Rest of Asia-Pacific Custom-Compounded Therapy, by Therapeutic Area USD Million (2018-2023)
  • Table 55. Europe Custom-Compounded Therapy, by Country USD Million (2018-2023)
  • Table 56. Europe Custom-Compounded Therapy, by Application USD Million (2018-2023)
  • Table 57. Europe Custom-Compounded Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 58. Europe Custom-Compounded Therapy, by Therapeutic Area USD Million (2018-2023)
  • Table 59. Germany Custom-Compounded Therapy, by Application USD Million (2018-2023)
  • Table 60. Germany Custom-Compounded Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 61. Germany Custom-Compounded Therapy, by Therapeutic Area USD Million (2018-2023)
  • Table 62. France Custom-Compounded Therapy, by Application USD Million (2018-2023)
  • Table 63. France Custom-Compounded Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 64. France Custom-Compounded Therapy, by Therapeutic Area USD Million (2018-2023)
  • Table 65. Italy Custom-Compounded Therapy, by Application USD Million (2018-2023)
  • Table 66. Italy Custom-Compounded Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 67. Italy Custom-Compounded Therapy, by Therapeutic Area USD Million (2018-2023)
  • Table 68. United Kingdom Custom-Compounded Therapy, by Application USD Million (2018-2023)
  • Table 69. United Kingdom Custom-Compounded Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 70. United Kingdom Custom-Compounded Therapy, by Therapeutic Area USD Million (2018-2023)
  • Table 71. Netherlands Custom-Compounded Therapy, by Application USD Million (2018-2023)
  • Table 72. Netherlands Custom-Compounded Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 73. Netherlands Custom-Compounded Therapy, by Therapeutic Area USD Million (2018-2023)
  • Table 74. Rest of Europe Custom-Compounded Therapy, by Application USD Million (2018-2023)
  • Table 75. Rest of Europe Custom-Compounded Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 76. Rest of Europe Custom-Compounded Therapy, by Therapeutic Area USD Million (2018-2023)
  • Table 77. MEA Custom-Compounded Therapy, by Country USD Million (2018-2023)
  • Table 78. MEA Custom-Compounded Therapy, by Application USD Million (2018-2023)
  • Table 79. MEA Custom-Compounded Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 80. MEA Custom-Compounded Therapy, by Therapeutic Area USD Million (2018-2023)
  • Table 81. Middle East Custom-Compounded Therapy, by Application USD Million (2018-2023)
  • Table 82. Middle East Custom-Compounded Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 83. Middle East Custom-Compounded Therapy, by Therapeutic Area USD Million (2018-2023)
  • Table 84. Africa Custom-Compounded Therapy, by Application USD Million (2018-2023)
  • Table 85. Africa Custom-Compounded Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 86. Africa Custom-Compounded Therapy, by Therapeutic Area USD Million (2018-2023)
  • Table 87. North America Custom-Compounded Therapy, by Country USD Million (2018-2023)
  • Table 88. North America Custom-Compounded Therapy, by Application USD Million (2018-2023)
  • Table 89. North America Custom-Compounded Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 90. North America Custom-Compounded Therapy, by Therapeutic Area USD Million (2018-2023)
  • Table 91. United States Custom-Compounded Therapy, by Application USD Million (2018-2023)
  • Table 92. United States Custom-Compounded Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 93. United States Custom-Compounded Therapy, by Therapeutic Area USD Million (2018-2023)
  • Table 94. Canada Custom-Compounded Therapy, by Application USD Million (2018-2023)
  • Table 95. Canada Custom-Compounded Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 96. Canada Custom-Compounded Therapy, by Therapeutic Area USD Million (2018-2023)
  • Table 97. Mexico Custom-Compounded Therapy, by Application USD Million (2018-2023)
  • Table 98. Mexico Custom-Compounded Therapy, by Distribution Channel USD Million (2018-2023)
  • Table 99. Mexico Custom-Compounded Therapy, by Therapeutic Area USD Million (2018-2023)
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Custom-Compounded Therapy: by Application(USD Million)
  • Table 110. Custom-Compounded Therapy Paediatric , by Region USD Million (2025-2030)
  • Table 111. Custom-Compounded Therapy Adult , by Region USD Million (2025-2030)
  • Table 112. Custom-Compounded Therapy Geriatric , by Region USD Million (2025-2030)
  • Table 113. Custom-Compounded Therapy Veterinary , by Region USD Million (2025-2030)
  • Table 114. Custom-Compounded Therapy: by Distribution Channel(USD Million)
  • Table 115. Custom-Compounded Therapy Hospital pharmacy , by Region USD Million (2025-2030)
  • Table 116. Custom-Compounded Therapy Compounding pharmacy , by Region USD Million (2025-2030)
  • Table 117. Custom-Compounded Therapy Others , by Region USD Million (2025-2030)
  • Table 118. Custom-Compounded Therapy: by Therapeutic Area(USD Million)
  • Table 119. Custom-Compounded Therapy Hormone replacement , by Region USD Million (2025-2030)
  • Table 120. Custom-Compounded Therapy Pain management , by Region USD Million (2025-2030)
  • Table 121. Custom-Compounded Therapy Dermatology , by Region USD Million (2025-2030)
  • Table 122. Custom-Compounded Therapy Specialty drugs , by Region USD Million (2025-2030)
  • Table 123. Custom-Compounded Therapy Nutritional supplements , by Region USD Million (2025-2030)
  • Table 124. Custom-Compounded Therapy Others , by Region USD Million (2025-2030)
  • Table 125. South America Custom-Compounded Therapy, by Country USD Million (2025-2030)
  • Table 126. South America Custom-Compounded Therapy, by Application USD Million (2025-2030)
  • Table 127. South America Custom-Compounded Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 128. South America Custom-Compounded Therapy, by Therapeutic Area USD Million (2025-2030)
  • Table 129. Brazil Custom-Compounded Therapy, by Application USD Million (2025-2030)
  • Table 130. Brazil Custom-Compounded Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 131. Brazil Custom-Compounded Therapy, by Therapeutic Area USD Million (2025-2030)
  • Table 132. Argentina Custom-Compounded Therapy, by Application USD Million (2025-2030)
  • Table 133. Argentina Custom-Compounded Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 134. Argentina Custom-Compounded Therapy, by Therapeutic Area USD Million (2025-2030)
  • Table 135. Rest of South America Custom-Compounded Therapy, by Application USD Million (2025-2030)
  • Table 136. Rest of South America Custom-Compounded Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 137. Rest of South America Custom-Compounded Therapy, by Therapeutic Area USD Million (2025-2030)
  • Table 138. Asia Pacific Custom-Compounded Therapy, by Country USD Million (2025-2030)
  • Table 139. Asia Pacific Custom-Compounded Therapy, by Application USD Million (2025-2030)
  • Table 140. Asia Pacific Custom-Compounded Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 141. Asia Pacific Custom-Compounded Therapy, by Therapeutic Area USD Million (2025-2030)
  • Table 142. China Custom-Compounded Therapy, by Application USD Million (2025-2030)
  • Table 143. China Custom-Compounded Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 144. China Custom-Compounded Therapy, by Therapeutic Area USD Million (2025-2030)
  • Table 145. Japan Custom-Compounded Therapy, by Application USD Million (2025-2030)
  • Table 146. Japan Custom-Compounded Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 147. Japan Custom-Compounded Therapy, by Therapeutic Area USD Million (2025-2030)
  • Table 148. India Custom-Compounded Therapy, by Application USD Million (2025-2030)
  • Table 149. India Custom-Compounded Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 150. India Custom-Compounded Therapy, by Therapeutic Area USD Million (2025-2030)
  • Table 151. South Korea Custom-Compounded Therapy, by Application USD Million (2025-2030)
  • Table 152. South Korea Custom-Compounded Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 153. South Korea Custom-Compounded Therapy, by Therapeutic Area USD Million (2025-2030)
  • Table 154. Taiwan Custom-Compounded Therapy, by Application USD Million (2025-2030)
  • Table 155. Taiwan Custom-Compounded Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 156. Taiwan Custom-Compounded Therapy, by Therapeutic Area USD Million (2025-2030)
  • Table 157. Australia Custom-Compounded Therapy, by Application USD Million (2025-2030)
  • Table 158. Australia Custom-Compounded Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 159. Australia Custom-Compounded Therapy, by Therapeutic Area USD Million (2025-2030)
  • Table 160. Rest of Asia-Pacific Custom-Compounded Therapy, by Application USD Million (2025-2030)
  • Table 161. Rest of Asia-Pacific Custom-Compounded Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 162. Rest of Asia-Pacific Custom-Compounded Therapy, by Therapeutic Area USD Million (2025-2030)
  • Table 163. Europe Custom-Compounded Therapy, by Country USD Million (2025-2030)
  • Table 164. Europe Custom-Compounded Therapy, by Application USD Million (2025-2030)
  • Table 165. Europe Custom-Compounded Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 166. Europe Custom-Compounded Therapy, by Therapeutic Area USD Million (2025-2030)
  • Table 167. Germany Custom-Compounded Therapy, by Application USD Million (2025-2030)
  • Table 168. Germany Custom-Compounded Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 169. Germany Custom-Compounded Therapy, by Therapeutic Area USD Million (2025-2030)
  • Table 170. France Custom-Compounded Therapy, by Application USD Million (2025-2030)
  • Table 171. France Custom-Compounded Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 172. France Custom-Compounded Therapy, by Therapeutic Area USD Million (2025-2030)
  • Table 173. Italy Custom-Compounded Therapy, by Application USD Million (2025-2030)
  • Table 174. Italy Custom-Compounded Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 175. Italy Custom-Compounded Therapy, by Therapeutic Area USD Million (2025-2030)
  • Table 176. United Kingdom Custom-Compounded Therapy, by Application USD Million (2025-2030)
  • Table 177. United Kingdom Custom-Compounded Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 178. United Kingdom Custom-Compounded Therapy, by Therapeutic Area USD Million (2025-2030)
  • Table 179. Netherlands Custom-Compounded Therapy, by Application USD Million (2025-2030)
  • Table 180. Netherlands Custom-Compounded Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 181. Netherlands Custom-Compounded Therapy, by Therapeutic Area USD Million (2025-2030)
  • Table 182. Rest of Europe Custom-Compounded Therapy, by Application USD Million (2025-2030)
  • Table 183. Rest of Europe Custom-Compounded Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 184. Rest of Europe Custom-Compounded Therapy, by Therapeutic Area USD Million (2025-2030)
  • Table 185. MEA Custom-Compounded Therapy, by Country USD Million (2025-2030)
  • Table 186. MEA Custom-Compounded Therapy, by Application USD Million (2025-2030)
  • Table 187. MEA Custom-Compounded Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 188. MEA Custom-Compounded Therapy, by Therapeutic Area USD Million (2025-2030)
  • Table 189. Middle East Custom-Compounded Therapy, by Application USD Million (2025-2030)
  • Table 190. Middle East Custom-Compounded Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 191. Middle East Custom-Compounded Therapy, by Therapeutic Area USD Million (2025-2030)
  • Table 192. Africa Custom-Compounded Therapy, by Application USD Million (2025-2030)
  • Table 193. Africa Custom-Compounded Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 194. Africa Custom-Compounded Therapy, by Therapeutic Area USD Million (2025-2030)
  • Table 195. North America Custom-Compounded Therapy, by Country USD Million (2025-2030)
  • Table 196. North America Custom-Compounded Therapy, by Application USD Million (2025-2030)
  • Table 197. North America Custom-Compounded Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 198. North America Custom-Compounded Therapy, by Therapeutic Area USD Million (2025-2030)
  • Table 199. United States Custom-Compounded Therapy, by Application USD Million (2025-2030)
  • Table 200. United States Custom-Compounded Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 201. United States Custom-Compounded Therapy, by Therapeutic Area USD Million (2025-2030)
  • Table 202. Canada Custom-Compounded Therapy, by Application USD Million (2025-2030)
  • Table 203. Canada Custom-Compounded Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 204. Canada Custom-Compounded Therapy, by Therapeutic Area USD Million (2025-2030)
  • Table 205. Mexico Custom-Compounded Therapy, by Application USD Million (2025-2030)
  • Table 206. Mexico Custom-Compounded Therapy, by Distribution Channel USD Million (2025-2030)
  • Table 207. Mexico Custom-Compounded Therapy, by Therapeutic Area USD Million (2025-2030)
  • Table 208. Research Programs/Design for This Report
  • Table 209. Key Data Information from Secondary Sources
  • Table 210. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Custom-Compounded Therapy: by Application USD Million (2018-2023)
  • Figure 5. Global Custom-Compounded Therapy: by Distribution Channel USD Million (2018-2023)
  • Figure 6. Global Custom-Compounded Therapy: by Therapeutic Area USD Million (2018-2023)
  • Figure 7. South America Custom-Compounded Therapy Share (%), by Country
  • Figure 8. Asia Pacific Custom-Compounded Therapy Share (%), by Country
  • Figure 9. Europe Custom-Compounded Therapy Share (%), by Country
  • Figure 10. MEA Custom-Compounded Therapy Share (%), by Country
  • Figure 11. North America Custom-Compounded Therapy Share (%), by Country
  • Figure 12. Global Custom-Compounded Therapy share by Players 2023 (%)
  • Figure 13. Global Custom-Compounded Therapy share by Players (Top 3) 2023(%)
  • Figure 14. Global Custom-Compounded Therapy share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Fagron (Netherlands) Revenue, Net Income and Gross profit
  • Figure 17. Fagron (Netherlands) Revenue: by Geography 2023
  • Figure 18. Specialist Pharmacy (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 19. Specialist Pharmacy (United Kingdom) Revenue: by Geography 2023
  • Figure 20. Nova Laboratories (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 21. Nova Laboratories (United Kingdom) Revenue: by Geography 2023
  • Figure 22. Athenex Pharma Solutions (New York) Revenue, Net Income and Gross profit
  • Figure 23. Athenex Pharma Solutions (New York) Revenue: by Geography 2023
  • Figure 24. ImprimisRx (California) Revenue, Net Income and Gross profit
  • Figure 25. ImprimisRx (California) Revenue: by Geography 2023
  • Figure 26. Fresenius Kabi (Germany) Revenue, Net Income and Gross profit
  • Figure 27. Fresenius Kabi (Germany) Revenue: by Geography 2023
  • Figure 28. Baxter (United States) Revenue, Net Income and Gross profit
  • Figure 29. Baxter (United States) Revenue: by Geography 2023
  • Figure 30. B. Braun (Germany) Revenue, Net Income and Gross profit
  • Figure 31. B. Braun (Germany) Revenue: by Geography 2023
  • Figure 32. Galenic Laboratories (France) Revenue, Net Income and Gross profit
  • Figure 33. Galenic Laboratories (France) Revenue: by Geography 2023
  • Figure 34. Global Custom-Compounded Therapy: by Application USD Million (2025-2030)
  • Figure 35. Global Custom-Compounded Therapy: by Distribution Channel USD Million (2025-2030)
  • Figure 36. Global Custom-Compounded Therapy: by Therapeutic Area USD Million (2025-2030)
  • Figure 37. South America Custom-Compounded Therapy Share (%), by Country
  • Figure 38. Asia Pacific Custom-Compounded Therapy Share (%), by Country
  • Figure 39. Europe Custom-Compounded Therapy Share (%), by Country
  • Figure 40. MEA Custom-Compounded Therapy Share (%), by Country
  • Figure 41. North America Custom-Compounded Therapy Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Fagron (Netherlands)
  • Specialist Pharmacy (United Kingdom)
  • Nova Laboratories (United Kingdom)
  • Athenex Pharma Solutions (New York)
  • ImprimisRx (California)
  • Fresenius Kabi (Germany)
  • Baxter (United States)
  • B. Braun (Germany)
  • Galenic Laboratories (France)
Additional players considered in the study are as follows:
Pencol Compounding Pharmacy (United States) , McKesson Corporation (United States) , Clinigen Group (United Kingdom)
Select User Access Type

Key Highlights of Report


Apr 2024 160 Pages 81 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Custom-Compounded Therapy Market Quantitative research analysis
Global Custom-Compounded Therapy Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Fagron (Netherlands), Specialist Pharmacy (United Kingdom), Nova Laboratories (United Kingdom), Athenex Pharma Solutions (New York), ImprimisRx (California), Fresenius Kabi (Germany), Baxter (United States), B. Braun (Germany) and Galenic Laboratories (France) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"New therapy are developing" is seen as one of major influencing trends for Custom-Compounded Therapy Market during projected period 2023-2030.
The Custom-Compounded Therapy market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Custom-Compounded Therapy Market Report?

Have a Query? Click Here

Other Related Reports

Health and Beauty Retailing Comprehensive Study by Type (Vegan, Organic, Inorganic), Distribution Channel (Online, Offline), Product (Skincare/Sun Care, Hair Care, Makeup and Color Cosmetic Products,...
$ 3450
Reperfusion Treatment Comprehensive Study by End users (Hospitals, Ambulatory surgery centers, Others), Treatment (Cyclosporin, Stem Cell Therapy, Therapeutic Hypothermia, Hydrogen Sulfide treatment,...
$ 3450
Ai in Hospital Management Comprehensive Study by Application (Administrative Workflows, Image Analysis, Robotic Surgery, Virtual Assistants, Clinical Decision Support, Others), Category (Patient-orie...
$ 3750
Radiology Microcatheters Comprehensive Study by Type (Delivery Microcatheters, Aspiration Microcatheters, Diagnostic Microcatheters, Steerable Microcatheters), Application (Cardiovascular, Neurovascu...
$ 3650
Electric Bobath Tables Comprehensive Study by Weight Capacity (< 200 Kg, 200-300 Kg, > 300 Kg), Sales Channel (Online, Offline), End-user (Clinics, Physiotherapists, Hospitals, Rehabilitation Centers...
$ 3500
Non-coding RNA Assays Comprehensive Study by Type (Infrastructural non coding RNA, Regulatory non coding RNA), End-User (Laboratories, Research Centers, Others), Size (Small, Medium, Large, Others) ...
$ 3500